GEN-MKT-18-7897-A
Mar 31, 2025 | Blogs, Pharma | 0 comments
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
Integration
Advanced analytical systems, like mass spectrometers and liquid chromatography systems, have a crucial role to play in guiding the pharmaceutical industry’s journey toward digital integration. We prioritize the development of expansive digital platforms that seamlessly merge various systems and data sources and establish robust standards. Embracing innovative technologies such as the internet of things and advanced analytics will allow us to implement real-time monitoring and predictive maintenance, ultimately optimizing operational efficiency for pharmaceutical companies.
Here is an example of An automated, real-time measurement of the kinetic hydrolysis of a glucuronide using the Echo® MS+ system with ZenoTOF 7600 system
Software
Embedding compliance features into our solutions is crucial to ensure alignment with evolving regulatory frameworks. Equally important, is a commitment to providing comprehensive training and continuous support to facilitate the smooth adoption of digital solutions within pharmaceutical companies. This proactive approach will empower our customers to navigate the complexities of digital transformation confidently and competently.
To allow our existing and potential new customers to trail our new software features, we provide a virtual trial of SCIEX OS software.
Register for a test drive SCIEX OS software, here.
Ultimately, we should aim to drive the industry toward achieving operational excellence within the interconnected digital landscape. Through ongoing innovation and strategic partnership, life science technology providers can make a meaningful impact in shaping the future of pharmaceutical operations, ensuring agility, resilience, and efficacy in an increasingly digital world.
Learn more about how SCIEX can help here
Electron-Activated Dissociation (EAD) is transforming the fields of metabolomics and lipidomics by providing enhanced fragmentation techniques that offer deeper insights into molecular structures. In September, Technology Networks hosted a webinar, “Enhancing Mass-Based Omics Analysis in Model Organisms,” featuring Dr. Valentina Calabrese from the Institute of Analytical Sciences at the University of Lyon. Valentina shared her insights on improving omics-based mass spectrometry analysis for toxicology studies using model organisms, particularly in metabolomics and lipidomics. This blog explores the additional functionalities EAD offers, its benefits in untargeted workflows, its incorporation into GNPS and molecular networking, and the future role it could play in these scientific domains.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained significant attention in the clinical laboratory due to its ability to provide best-in-class sensitivity and specificity for the detection of clinically relevant analytes across a wide range of assays. For clinical laboratories new to LC-MS/MS, integrating this technology into their daily routine operations may seem like a daunting task. Developing a clear outline and defining the requirements needed to implement LC-MS/MS into your daily operations is critical to maximize the productivity and success of your clinical laboratory.
In today’s rapidly evolving food industry, the role of food testing laboratories has never been more critical. Ensuring the safety, quality, and authenticity of food products is paramount, and this responsibility falls heavily on the shoulders of laboratory managers. The economics of food testing—encompassing everything from high-throughput pesticide screening to advanced research on alternative protein sources—plays a pivotal role in shaping the operational efficiency and financial health of these laboratories.
Posted by
You must be logged in to post a comment.
Share this post with your network